iBio, Inc. (IBPM.OB) Teams up with Two Strong Industry Players to Develop and Market Biopharmaceutical Solutions
Biopharmaceutical company iBio Inc. is commercializing its proprietary iBioLaunch(TM) platform to produce biologics including vaccines and therapeutic proteins. The company today announced that it has entered into a joint agreement with its development collaborator Fraunhofer USA Center for Molecular Biotechnology (CMB), and GE Healthcare, a unit of General Electric Company (NYSE: GE), to collaboratively develop and globally market manufacturing solutions for biopharmaceuticals and vaccines based upon their respective proprietary technologies. Financial terms of the agreement were not disclosed. The initiative combines GE Healthcare's capabilities and worldwide presence in life sciences, iBio's iBioLaunch plant-based vaccine and therapeutic protein manufacturing platform, and…